| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,270,000 |
| Market
Cap: |
279.72(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.29 - $37.61 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 8.1 |
| Insider 6 Months : 8.1 |
| Insider 3/6 Months : 16.7 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Revance Therapeutics is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. Co.'s segments are: Product, which refers to the business that includes the research, development and commercialization of its product candidates and the RHA® Collection of dermal fillers; and Service, which refers to the business that includes the development and commercialization of the OPUL™ Relational Commerce Platform and HintMD platform.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
30,000 |
30,000 |
30,000 |
30,000 |
| Total Buy Value |
$209,400 |
$209,400 |
$209,400 |
$209,400 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
29,089 |
29,089 |
295,146 |
446,160 |
| Total Sell Value |
$143,717 |
$143,717 |
$8,000,388 |
$12,719,522 |
| Total People Sold |
4 |
4 |
5 |
5 |
| Total Sell Transactions |
4 |
4 |
18 |
27 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Sjuts Dustin S |
President |
• – – |
2022-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
52,396 |
145,442 |
|
- |
|
| Moxie Dwight |
SVP, GC & Secretary |
• – – |
2022-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
42,349 |
74,043 |
|
- |
|
| Schilke Tobin |
CFO |
• – – |
2022-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
42,349 |
91,739 |
|
- |
|
| Moxie Dwight |
SVP, GC & Secretary |
• – – |
2022-09-14 |
4 |
AS |
$27.07 |
$297,798 |
D/D |
(11,000) |
31,694 |
|
23% |
|
| Sjuts Dustin S |
President |
• – – |
2022-06-30 |
4 |
A |
$11.75 |
$11,747 |
D/D |
1,000 |
98,123 |
|
- |
|
| Foley Mark J |
CEO |
• • – |
2022-06-30 |
4 |
A |
$11.75 |
$11,747 |
D/D |
1,000 |
766,761 |
|
- |
|
| Schilke Tobin |
CFO |
• – – |
2022-06-30 |
4 |
A |
$11.75 |
$11,336 |
D/D |
965 |
63,490 |
|
- |
|
| Joshi Abhay |
COO, President of R&D |
• – – |
2022-03-15 |
4 |
D |
$15.79 |
$41,165 |
D/D |
(2,607) |
120,708 |
|
- |
|
| Sjuts Dustin S |
President |
• – – |
2022-03-15 |
4 |
D |
$15.79 |
$28,975 |
D/D |
(1,835) |
97,123 |
|
- |
|
| Foley Mark J |
Chief Executive Officer |
• • – |
2022-03-15 |
4 |
D |
$15.79 |
$52,170 |
D/D |
(3,304) |
765,761 |
|
- |
|
| Rankin Aubrey |
Director |
– • – |
2022-03-15 |
4 |
D |
$15.79 |
$21,664 |
D/D |
(1,372) |
94,091 |
|
- |
|
| Schilke Tobin |
Chief Financial Officer |
• – – |
2022-03-15 |
4 |
D |
$15.79 |
$41,165 |
D/D |
(2,607) |
62,525 |
|
- |
|
| Moxie Dwight |
SVP, GC & Secretary |
• – – |
2022-03-15 |
4 |
D |
$15.79 |
$80,687 |
D/D |
(5,110) |
42,694 |
|
- |
|
| Sjuts Dustin S |
President |
• – – |
2022-02-15 |
4 |
D |
$13.35 |
$32,427 |
D/D |
(2,429) |
98,958 |
|
- |
|
| Joshi Abhay |
COO, President, R&D |
• – – |
2022-02-15 |
4 |
D |
$13.35 |
$67,458 |
D/D |
(5,053) |
123,315 |
|
- |
|
| Schilke Tobin |
CFO |
• – – |
2022-02-15 |
4 |
D |
$13.35 |
$39,035 |
D/D |
(2,924) |
65,132 |
|
- |
|
| Foley Mark J |
CEO |
• • – |
2022-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
175,649 |
993,659 |
|
- |
|
| Sjuts Dustin S |
President |
• – – |
2022-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
52,395 |
173,362 |
|
- |
|
| Moxie Dwight |
SVP, GC & Secretary |
• – – |
2022-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
42,349 |
90,566 |
|
- |
|
| Schilke Tobin |
CFO |
• – – |
2022-02-02 |
4 |
A |
$0.00 |
$0 |
D/D |
42,349 |
105,430 |
|
- |
|
| Schilke Tobin |
CFO |
• – – |
2021-12-31 |
4 |
A |
$13.87 |
$5,604 |
D/D |
404 |
68,056 |
|
- |
|
| Sjuts Dustin S |
President |
• – – |
2021-12-15 |
4 |
D |
$15.92 |
$8,167 |
D/D |
(513) |
101,387 |
|
- |
|
| Schilke Tobin |
CFO |
• – – |
2021-12-15 |
4 |
D |
$15.92 |
$24,772 |
D/D |
(1,556) |
67,652 |
|
- |
|
| Russell Angus C. |
Director |
– • – |
2021-12-13 |
4 |
B |
$15.74 |
$100,741 |
D/D |
6,400 |
26,913 |
2.39 |
12% |
|
| Rankin Aubrey |
President, Innovation & Tech |
• • – |
2021-12-03 |
4 |
B |
$14.43 |
$432,876 |
D/D |
30,000 |
95,463 |
2.81 |
27% |
|
415 Records found
|
|
Page 4 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.11 (3.34%) 
